Episode 139: Follicular Lymphoma Series, Pt 4 - Relapsed/Refractory Management (Cellular therapy options)

Episode 139: Follicular Lymphoma Series, Pt 4...

Up next

Episode 161: Career Development Series- Building a Career in Clinical Research

This week, we are so excited to share the third episode of our Career Development Series episodes, developed in partnership with The American Society of Hematology, The ASH Trainee Council, and Hematopoiesis! For years, our listeners have reached out to our show asking for guidan ...  Show more

Episode 160: Head and Neck Cancer Series, Pt. 3 – Discussion with ENT

Throughout this series, we have discussed how multidisciplinary the management of head and neck cancer is and the critical role that our surgical colleagues play in the management of this disease. This week, we welcome Dr. Michael Topf, Associate Professor for Associate Professor ...  Show more

Recommended Episodes

Follicular Lymphoma
Two Onc Docs

This week’s episode will be focusing on one of the Non-Hodgkin Lymphomas: Follicular Lymphoma. We will go over the important details on diagnostic criteria, indications for treatment and treatment options.

 

Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation
Blood Podcast

In this week's episode, we’ll learn more about mechanisms of primary resistance to BCMA-targeted bispecific T-cell engagers in relapsed/refractory multiple myeloma, the effects of emapalumab therapy on outcomes in patients with pediatric hemophagocytic lymphohistiocytosis who rec ...  Show more

Episode 64. Lymphoma Updates from EHA and ICML 2025 with Dr. Adrian Minson
Blood Cancer Talks

In this episode of Blood Cancer Talks, we have Dr. Adrian Minson from the Peter MacCallum Cancer Centre to discuss the latest developments in lymphoma presented at the recent EHA and ICML meetings in June 2025. The episode focuses primarily on the emerging role of bispecific anti ...  Show more

Multiple Myeloma
Two Onc Docs

This week’s episode is part 2 of our plasma cell dyscrasias series. We will go over the important details on risk stratification, as well as initial and relapse treatment options for Multiple Myeloma, with key details on the pharmacology of myeloma drugs.